At TCT 2019, the COAPT trial again held center stage, as three-year follow-up of patients in the trial was presented.

There were also reports on quality of life outcomes and cost effectiveness, which answered yes or no questions: Does MitraClip improve quality of life for patients with MR? Does the cost merit its use?

In both reports at TCT, the answer was an unqualified affirmative. However, which patients benefit most from the MitraClip? Thar answer is not so straightforward. Read more.

Follow Cardiology on Twitter using #CardiologyMag and get the full issue here.